GoldenGolden
Advanced Search
Codexis

Codexis

An enzyme engineering company supplying products to commercial customers and developing proteins for its own portfolio of clinical biologics.

Codexis was incorporated in 2002 by Maxygen to develop an enzyme engineering technology platform, completing a spin-off in 2010 as a separate publicly-listed company on the NASDAQ exchange. The company is making enzymes for companies operating in the following industries: pharmaceuticals, biotherapeutics, food & beverage, and molecular diagnostics.

Funding
Growth

On June 20, 2019 Codexis completed a growth funding round with $50 million in funding from Casdin Capital. The funding is through a private placement of Codexis common stock, and will be used to fund strategic growth initiatives for the companies activity in the synthetic biology market. The president and CEo of Codexis made the following public statement regarding Casdin Capital's investment:

The value and the versatility of Codexis’ business and engineering platform enables a diverse set of high-growth capabilities across multiple markets. Casdin has long recognized our technology and leadership capability and, with their latest investment, we have significant financial flexibility to capitalize on a variety of growth opportunities.

Timeline

December 2020
Codexis raises a $75,000,000 venture round.
2008
Codexis was founded by Alan Shaw and Gjalt Huisman.
August 14, 2006
Codexis raises a $37,000,000 series D round from Chevron Technology Ventures and Maxygen.

Funding rounds

People

Name
Role
LinkedIn

Adam Litle

Employee

Barry Ettenger

Employee

Brian Kirshner

Employee

Christopher McCarthy

Employee

Darla Llewelyn

Employee

David J. Galgoczy

Employee

David McCaman, CPA

Employee

Dayna H. Johnson

Employee

Diana Maichin

Employee

Gordon Sangster

Senior Vice President, CFO

Gregg Ringold

Employee

Gregory Miller

Employee

Jim Lalonde

Senior Vice President of R&D

John Nichols

President, CEO

John Vu

Employee

Joshua Geilhufe

Employee

Kamrin Mac Knight

Employee

Kiyoung Paik

Employee

Lana Spencer, PG, CHMM, QISP

Advisor

Lisa Moore

Employee

Lucia Guh-Siesel

Attorney

Melvina Ho

Employee

Michael Aldridge

Corporate and Strategic Development

Monica Bhatia

Employee

Navneet Chagger

Employee

Page 1 of 2

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Research and Markets
June 1, 2021
www.prnewswire.com:443
/PRNewswire/ -- The "Global Enzymes Market By Source, By Type, By Reaction Type, By Application, By Regional Outlook, Industry Analysis Report and Forecast,...
January 14, 2021
WebWire
Tate & Lyle (LSE: TATE.L), a leading global provider of food ingredients and solutions, and Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company and developer of high-performance enzymes, have extended and deepened their relationship to enhance the production of two of Tate & Lyle's newest sweeteners: DOLCIA PRIMA® Allulose and TASTEVA® M Stevia Sweetener. Codexis' latest novel enzyme products, generated in close collaboration with Tate & Lyle's experts, will enable additi...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.